Disease · MONDO_0005101

ulcerative colitis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. ulcerative colitis. Diseases, record MONDO_0005101. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005101

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: ulcerative colitis; Open Targets
Open Targets ID: MONDO_0005101; Open Targets
Other names: Colitis, Ulcerative, Left-sided ulcerative (chronic) colitis, Left-sided ulcerative colitis, Other ulcerative colitis, Other ulcerative colitis (disorder), UC, UC - ulcerative colitis, ULCERATVE COLITIS UNSPCF, Ulcerative colitis, unspecified, ulcerative colitis (disease), ulcerative colitis (disorder); Open Targets
Disease Ontology: DOID:8577; Disease Ontology
MeSH: D003093; MeSH
NCI Thesaurus: C2952; NCI Thesaurus
Orphanet: ORPHA:771; Orphanet
Highest stage of its drugs: Approval, for 32 of its 241 drugs, from DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs241

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
MESALAMINE	CHEMBL704	Small molecule	Approval	DailyMed, PMDA and TTD	125	78	74	Drugs and targets
VEDOLIZUMAB	CHEMBL1743087	Antibody	Approval	DailyMed, EMA Human Drugs and PMDA	71	67	67	Drugs and targets
INFLIXIMAB	CHEMBL1201581	Antibody	Approval	DailyMed, EMA Human Drugs and PMDA	77	65	65	Drugs and targets
ADALIMUMAB	CHEMBL1201580	Antibody	Approval	DailyMed, EMA Human Drugs and PMDA	55	38	38	Drugs and targets
GOLIMUMAB	CHEMBL1201833	Antibody	Approval	DailyMed, EMA Human Drugs and PMDA	31	26	26	Drugs and targets
USTEKINUMAB	CHEMBL1201835	Antibody	Approval	EMA Human Drugs	29	21	21	Drugs and targets
MIRIKIZUMAB	CHEMBL3990014	Antibody	Approval	EMA Human Drugs, FDA, PMDA and TTD	22	17	17	Drugs and targets
UPADACITINIB	CHEMBL3622821	Small molecule	Approval	EMA Human Drugs	18	16	16	Drugs and targets
BUDESONIDE	CHEMBL1370	Small molecule	Approval	DailyMed and PMDA	17	14	14	Drugs and targets
ETRASIMOD	CHEMBL3358920	Small molecule	Approval	EMA Human Drugs and TTD	16	14	14	Drugs and targets

1 to 10 of 241

See all 241 drugs

Targets236

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	19	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
JAK1	Janus Kinase (JAK)	9	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitor	Approval	https://conductscience.org/library/genes/3716	Drugs and targets
TYK2	Janus Kinase (JAK)	9	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase TYK2 negative allosteric modulator	Approval	https://conductscience.org/library/genes/7297	Drugs and targets
JAK3	Janus Kinase (JAK)	7	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK3 inhibitor	Approval	https://conductscience.org/library/genes/3718	Drugs and targets
S1PR1	Sphingosine 1-phosphate receptor	7	Sphingosine 1-phosphate receptor Edg-1 agonist; Sphingosine 1-phosphate receptor Edg-1 modulator; Sphingosine 1-phosphate receptor modulator	Approval	https://conductscience.org/library/genes/1901	Drugs and targets
IL12B	Interleukin-12	6	Interleukin-12 inhibitor; Interleukin-23 inhibitor	Approval	https://conductscience.org/library/genes/3593	Drugs and targets
IL23A	Interleukin-23	6	Interleukin-23 inhibitor	Approval	https://conductscience.org/library/genes/51561	Drugs and targets
JAK2	Janus Kinase (JAK)	6	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitor	Approval	https://conductscience.org/library/genes/3717	Drugs and targets
ALOX5	Polyunsaturated fatty acid 5-lipoxygenase	5	Arachidonate 5-lipoxygenase inhibitor	Approval	https://conductscience.org/library/genes/240	Drugs and targets
PPARG	Peroxisome proliferator-activated receptor gamma	5	Peroxisome proliferator-activated receptor gamma agonist	Approval	https://conductscience.org/library/genes/5468	Drugs and targets

1 to 10 of 236

See all 236 targets

Trials592

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 12 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02539368	Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease		2,565	2020-02-13	Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn's Disease	INFLIXIMAB	Its record names the disease	ClinicalTrials.gov
NCT00790933	An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease	Phase 3	2,243	2019-03-12	Ulcerative Colitis, Crohn's Disease	VEDOLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00705484	European Safety Registry in Ulcerative Colitis (P04808)		2,239	2018-07-24	Ulcerative Colitis	INFLIXIMAB	Its record names the disease	ClinicalTrials.gov
NCT02118584	Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies	Phase 3	1,822	2024-10-23	Ulcerative Colitis	ETROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03398148	A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis	Phase 2/3	1,558	2025-01-16	Ulcerative Colitis (UC)	RISANKIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02914522	Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis	Phase 3	1,351	2021-04-21	Ulcerative Colitis	FILGOTINIB	Its record names the disease	ClinicalTrials.gov
NCT03524092	A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis	Phase 3	1,328	2022-11-25	Ulcerative Colitis	MIRIKIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02819635	A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)	Phase 2/3	1,302	2022-06-30	Ulcerative Colitis (UC)	UPADACITINIB	Its record names the disease	ClinicalTrials.gov
NCT03518086	An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)	Phase 3	1,281	2022-02-28	Ulcerative Colitis	MIRIKIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00488631	An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis	Phase 3	1,228	2013-11-11	Colitis, Ulcerative	GOLIMUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 592

See all 592 trials

Comparisons in its trials191

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Part 1 (OLE): Etrolizumab vs Part 2 (PML SM): deaths from any cause	9 of 1,773	1 of 796	2,569	NCT02118584	Trial comparisons
Part 1 (OLE): Etrolizumab vs Part 2 (PML SM): serious adverse events	373 of 1,773	2 of 796	2,569	NCT02118584	Trial comparisons
Vedolizumab 300 mg (UC) vs Vedolizumab 300 mg (CD): Number of Participants With at Least One Clinically Significant Electrocardiogram (ECG) Findings	7 of 894	7 of 1,349	2,243	NCT00790933	Trial comparisons
MMX Mesalamine/ Mesalazine (Acute Phase) vs MMX Mesalamine/ Mesalazine (Maintenance Phase): serious adverse events	13 of 717	14 of 461	1,178	NCT01124149	Trial comparisons
Mesalamine Once-Daily vs Mesalamine Twice-Daily: Number of Subjects Who Relapse/Flare Within 6 Months, ITT Population	45 of 512	39 of 511	1,023	NCT00505778	Trial comparisons
Mesalamine Once-Daily vs Mesalamine Twice-Daily: serious adverse events	18 of 512	9 of 511	1,023	NCT00505778	Trial comparisons
Tofacitinib 5 mg BID vs Tofacitinib 10 mg BID: Number of Participants With Serious Infections as Treatment Emergent Adverse Events (TEAEs)	8 of 175	31 of 769	944	NCT01470612	Trial comparisons
Tofacitinib 5 mg BID vs Tofacitinib 10 mg BID: deaths from any cause	0 of 175	6 of 769	944	NCT01470612	Trial comparisons
Tofacitinib 5 mg BID vs Tofacitinib 10 mg BID: Number of Participants With Clinically Significant Changes in Physical Examinations From Baseline	84 of 175	391 of 769	944	NCT01470612	Trial comparisons
Tofacitinib 5 mg BID vs Tofacitinib 10 mg BID: serious adverse events	39 of 175	147 of 769	944	NCT01470612	Trial comparisons

1 to 10 of 191

See all 191 comparisons in its trials

Papers from its trials418

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39321363	RESULT	1	PubMed
39236736	RESULT	1	PubMed
37224198	RESULT	1	PubMed
35673354	RESULT	1	PubMed
35644166	RESULT	3	PubMed
35306553	RESULT	1	PubMed
33676969	RESULT	2	PubMed
33245002	RESULT	1	PubMed
33188747	RESULT	1	PubMed
32804854	RESULT	1	PubMed

1 to 10 of 418

See all 418 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005101

GET https://conductscience.org/api/diseases/v1/MONDO_0005101/drugs?page=2

API reference For AI assistants